Matthew Shinkle is an Online Content Editor at Healio, where he focuses on medical journalism, particularly in the areas of hematology, oncology, and immunology. With a background in sports broadcasting and extensive experience as a newspaper reporter, Shinkle combines his passion for health and wellness with his journalistic skills. He has been featured in Haddonfield Sun, Healio, and LessWrong 2.0.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Matthew Shinkle's coverage predominantly revolves around healthcare and pharmaceuticals, focusing on scientific research and data-driven insights. Given the emphasis on citing data, pitches to him should provide robust scientific evidence or studies that uncover significant advancements or disparities in cancer treatment. Additionally, given his focus on racial disparities and drug therapy, he may be interested in stories concerning innovative approaches to addressing these issues.
Sources with a deep understanding of clinical trials and medical research could effectively engage Matthew through providing valuable context for new therapies, especially those related to breast cancer, lymphoma, or drugs targeting specific patient populations.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Heather Biele, Matthew Shinkle
The Oakland score outperformed several risk assessments and should be used alongside clinical judgment when determining which patients with lower gastrointestinal bleeding can be safely discharged, according to study results.
By: Heather Biele, Matthew Shinkle
Use of an electronic health record-based marker could help clinicians identify liver transplant recipients who are at risk for organ rejection due to medication nonadherence.
By: Heather Biele, Matthew Shinkle
The FDA has expanded a safety alert warning consumers to avoid certain botanical weight loss supplements that contain toxic yellow oleander.
By: Kristen Dowd, Matthew Shinkle
Key takeaways: The FDA approved Zenbexus for treatment of multiple myeloma.
By: Sarah A. Coggins, Matthew Shinkle
Newborn females are significantly less likely to receive intramuscular vitamin K prophylaxis and slightly less likely to receive the hepatitis B vaccine than newborn males, according to retrospective cohort study data. Findings published in JAMA Network Open from three centers in the University of Pennsylvania health system showed that overall parental decline of both vitamin K prophylaxis and
By: Matthew Shinkle, Kristen Dowd
Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE
By: Matthew Shinkle, Kristen Dowd
The FDA approved two zanidatamab-hrii-based regimens as first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
By: Matthew Shinkle, Heather Biele, Sarah A. Coggins
Parental refusal of the newborn hepatitis B virus vaccine surged in recent years, the latest in an ongoing trend that has more than doubled refusal rates since 2018, according to study results published in JAMA Network Open
By: Matthew Shinkle, Heather Biele
Video Player is loading. Play Video Play Mute Current Time Duration Loaded Stream Type LIVE
By: Matthew Shinkle, Shenaz Bagha
Several dietary elements recommended in the 2025-2030 Dietary Guidelines for Americans, including total protein intake and red meat, have been linked to steatotic liver disease and fibrosis, analyses showed.
